Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database
Saved in:
Published in | Haematologica (Roma) Vol. 109; no. 7; pp. 2277 - 2289 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Italy
Fondazione Ferrata Storti
29.02.2024
Ferrata Storti Foundation |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Bibliography: | SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Correspondence-1 content type line 23 ObjectType-Article-3 Disclosures JRB discloses consultancy for AbbVie, Acerta/AstraZeneca, Alloplex Biotherapeutics, BeiGene, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, InnoCare Pharma Inc, iOnctura, Kite, Loxo/ Lilly, Merck, Numab Therapeutics, Pfizer and Pharmacyclics; research funding from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma and TG Therapeutics. PG discloses honoraria from AbbVie, ArQule/MSD, AstraZeneca, BeiGene, Celgene/Juno/Bristol Myers Squibb, Janssen, Lilly/Loxo, MEI Pharma, Roche and Sanofi; research funding from AbbVie, AstraZeneca, Janssen and Sunesis. WJ discloses consultancy for Janssen, AstraZeneca, MEI Pharma, Lilly, Takeda, Roche, AbbVie and BeiGene; research funding from AbbVie, Bayer, BeiGene, Celgene, Janssen, Roche, Takeda, TG Therapeutics, AstraZeneca, MEI Pharma and Lilly. BSK discloses research funding from BeiGene to Washington University School of Medicine (St Louis, MO, USA); consulting fees from AbbVie, AstraZeneca, BeiGene, Janssen and Pharmacyclics. NL discloses consultancy for AbbVie, AstraZeneca, BeiGene, Lilly/Loxo, Genentech, Janssen and Pharmacyclics; research funding from AbbVie, AstraZeneca, BeiGene, Lilly/Loxo, Genentech, Octapharma, Oncternal, MingSight and TG Therapeutics. TR discloses research funding from BeiGene, Octapharma, AstraZeneca, Janssen, Regeneron and GSK; honoraria from AstraZeneca, BeiGene, Janssen, AbbVie, Octapharma, Regeneron and GSK; travel, accommodations, expenses from AstraZeneca. MS discloses consultancy for AbbVie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Lilly, Adaptimmune, Mustang Bio, Regeneron, Merck, Fate Therapeutics, MEI Pharma and Atara Biotherapeutic; research funding from Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, AbbVie, TG Therapeutics, BeiGene, AstraZeneca, Sunesis, Atara Biotherapeutics, Genmab, MorphoSys/Incyte and Vincerx. CST discloses research funding from Janssen, AbbVie and BeiGene; honoraria from Janssen, AbbVie, BeiGene, Loxo and AstraZeneca. LQ discloses consultancy for and speakers bureau of Janssen, AstraZeneca, Takeda, Roche, AbbVie and BeiGene. TS discloses employment at BeiGene Switzerland GmbH; is an equity holder of BeiGene Ltd. MZ, JP, LW, JZ and HM disclose employment at BeiGene. AC discloses employment at BeiGene; is an equity holder of BeiGene; discloses travel, accommodations, expenses from BeiGene. AT discloses consultancy for BeiGene, AstraZeneca, AbbVie and Janssen; honoraria from BeiGene, AstraZeneca, AbbVie and Janssen; speakers bureau of BeiGene, AstraZeneca, AbbVie and Janssen; travel, accommodations, expenses from BeiGene, AstraZeneca, AbbVie and Janssen. Contributions JRB, PG, WJ, BSK, NL, TR, MS, CST, LQ, and AT enrolled patients, performed research, and contributed to data collection, analysis, and interpretation. JP, TS, LW, MZ, AC, and HM contributed to this study’s conceptualization and design, data curation, formal analysis, data interpretation, methodology, and validation. All authors contributed to the writing, review, editing, and final approval of this manuscript. |
---|---|
ISSN: | 0390-6078 1592-8721 1592-8721 |
DOI: | 10.3324/haematol.2023.283846 |